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Introduction: Personalization of Cancer
Care for Older Adults
“The best tunes are played on the oldest ﬁddles”
Rick Blain (Casablanca)
Our population is aging. In June of 2020, the US census
bureau published a ﬁgure demonstrating the change in the
age of our population since 2010 (https://www.census.gov/
library/visualizations/2020/comm/a-wave-of-change.html).
Every age group from 55 years and above has increased in
population, while every age group 20 and lower has
decreased. By 2040, it is estimated that > 70% of all patients
diagnosed with cancer will be age 65 or older.1 Yet, old is a
relative term. The chronologic deﬁnition of old age is and
will always be a moving target. Humans, even within the
same society, do not all biologically age at the same rate.
Thus, a deﬁnition of old age which includes the biological
changes that lead to physical or functional decline is better
suited for the needs of patients and physicians attempting to
make complex decisions regarding cancer care. After all, “the
number of rotations the earth has made around the sun since
a person’s birth” does not inherently change that person’s
suitability for cancer treatment. Just like the beautiful and
deep tones of an older ﬁddle, the depth of experience and
wisdom of older adults should be fully appreciated by
clinicians.
Yet, an older proverbial ﬁddle “on the roof” balancing at
times precariously due to its potentially more fragile state
must be handled with the utmost care and consideration.
Indeed, the aging process is often associated with the decline
of multiple organ systems over time.2 This decline can lead
to a loss of functional reserve and ability to recover from
harm that may occur to those organs. Older adults with
functional decline associated with aging may have less tolerance to and thus less beneﬁt from standard cancer therapies,
including chemotherapy, immunotherapy, surgery, and/or
radiation. Therefore, such “older” patients should not be
approached or treated in the same manner as healthier, functionally intact, younger patients. However, how these
patients should be treated is still unclear because they are
often poorly represented in standard-setting trials, 3 leaving
physicians with little data to support their treatment recommendations. This lack of evidence to support optimal treatments for older adult patients can lead to over-treatment in

some and under-treatment in others.4 Unfortunately, the
“eye-ball” test of older adults and even basic assessments,
such as Karnofsky Performance Status, cannot adequately
identify important functional deﬁcits or predict which older
adults can tolerate anti-neoplastic therapies.5,6 Thankfully,
over the last couple of decades, the ﬁeld of geriatric oncology
has developed tools to help cancer physicians better identify
important clinical variables that can predict important outcomes and allow oncologists to personalize the treatment of
older adults with cancer.
Ten years ago, this journal published a special edition on
Cancer, Aging, and Comorbidities.7 Since then, signiﬁcant
changes and improvements have been made in geriatric
oncology. In this issue of Seminars in Radiation Oncology,
entitled “Personalization of Cancer Care For Older Adults”,
updates in the care of older adults and how these can be
translated into oncology now and in the future are featured.
The implementation of assessments of older adults with cancers are now being used in multiple settings to help clinicians
and their patients make treatment decisions. Surgical oncologists can use these assessments to help decide on the best
approaches for resection including who would beneﬁt from
robotic or minimally invasive approaches.8 Medical oncologists can use assessments to predict cytotoxic chemotherapy
toxicity and who would beneﬁt from dose-reduced treatments or targeted agents.9,10 New studies also suggest that
intervening on the assessment’s ﬁndings can reduce toxicity
from chemotherapy.11,12 While this issue will focus on how
these assessments can impact the ﬁeld of radiation oncology,
these principles apply across the entire multidisciplinary cancer team, including not only medical and surgical oncologists, but also the important roles of nurses, navigators,
psycho-oncologists, physicists, therapists, and so many
more.
Radiation oncologists may see a greater portion of older
patients who are deemed ineligible for surgery or intensive
systemic chemotherapy, due to the potentially lower rate of
systemic toxicities from radiotherapy compared to cytotoxic
drugs, or general anesthesia. Thus, radiation oncologists
must understand how age and the aging process can impact
our choices for appropriate care. Radiotherapy is a local and/
or regional treatment, thus, the impact that comorbidities
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have on tolerance to radiotherapy may be very different from
how they impact surgery or systemic therapy. Moreover, a
comorbidity’s association with tolerance to radiotherapy will
be different depending on the area of the body being irradiated. Due to the daily nature of many of our treatments, a
decline in physical function or social function, such as the
inability to drive or ﬁnd transportation, could impact radiation treatments more so than with other ﬁelds. At the same
time, the daily visits often required for radiotherapy, also
allow multiple opportunities for interventions to help reduce
possible side effects associated with aging.
The very nature of radiotherapy treatments allows for
more personalized treatment for patients. In our image-based
planning, radiotherapy is personalized to the anatomy (and
at times functional anatomy) of the individual patient. Adaptive radiation planning, including newer techniques such as
MR-guided adaptive radiotherapy, can even allow for realtime changes in treatment planning personalized to the
patient’s “anatomy of the moment”.13 Some have even suggested genome-based adjustments to radiation doses which
may allow future radiation oncologists to better estimate the
risk and beneﬁt of radiotherapy doses for their patients.14
The personalized treatment our ﬁeld already delivers could
be made even more appropriate by incorporating functional
assessments, comorbidities, quality of life, social factors, and
other geriatric principles into our treatment decisions and
deliveries. A screening geriatric assessment (GA) (discussed
in more detail in the ﬁrst and last articles), completed before
treatment, could help predict life expectancy (eg, eprognosis.
ucsf.edu), expected toxicity from chemotherapy,15 postoperative morbidities,16 post-radiotherapy quality of life,17 and
could identify social issues including transportation problems. Any of the above, if identiﬁed before treatment, can
help both clinicians and patients decide on the best treatment options, whether choosing to attempt single modality
versus trimodality, palliative intent treatment versus curative
intent, or choosing a shorter (hypofractionated or stereotactic) radiotherapy course. As eloquently expressed by Licthman et al. “[Geriatric assessment] results can be more
important than the results of a molecular study or a scan,
and the acting on GA information is personalized medicine
in its highest form”.18
In the ﬁrst review of this issue, Outlaw et al. discuss the
history of the ﬁeld of geriatric oncology and how the GA has
evolved over the last decade. Speciﬁcally, they review how
these assessments are currently being used in clinical trials
and several oncology clinics to better inform cancer treatment decisions and to implement interventions that could
improve cancer tolerance Multiple geriatric assessment
options and their interpretation are detailed as a roadmap to
help clinicians implement those assessments in their clinics.
In the second review, O’Donovan et al. discuss how radiation
oncologists are beginning to implement some of these tools
into their clinics and trials. Additionally, they discuss the
results of a recently published survey of radiation oncologists
demonstrating the continued interest in these assessments,
but the need for more knowledge and experience to fully
implement them. In the next review, Morris et al, highlight

the importance of educating those who work in radiation
oncology clinics (therapists, nurses, physicians, etc.) on
important geriatric principles to more rapidly and efﬁciently
implement the improvements necessary to upgrade treatments for older adults. In the fourth review, Ludmir et al
highlight why obtaining the evidence necessary to improve
the care of older adults has been so difﬁcult. For decades,
clinical trials (both run by industry and the cooperative
groups), have largely disparately accrued younger and
healthier patients into trials that set the standards of care for
most cancers.19,20 The authors highlight efforts underway to
improve clinical trial designs which will lead to narrowing of
the evidence gaps that exist in how to care for older adults
with cancer.
In the next set of reviews, we emphasize important
updates in the ﬁeld of radiation oncology speciﬁcally, which
can be implemented to improve the care of older adults. Tsai
et al discuss the treatment of oligometastatic disease and how
radiotherapy has evolved to improve the care of older patients
with stage IV disease as well as their younger peers. The next
review by Germino et. al highlights the use of combined
immunotherapy and radiotherapy and speciﬁes ongoing trials
of such treatments within older patient populations. The next
three mini-reviews all discuss the role of hypofractionation in
older adults. The ﬁrst by Kunkler reviews the role of hypofractionation and ultra-hypofractionation within breast cancer.
Edmonston et al, discuss treatment options in patients with
GBM and offer ways in which treatment choices could be
based on functional assessments. Zhang-Velton and Sanford
review the role of shorter radiation courses in patients with
GI cancers and offer recommendations on when best to use
hypofractionated courses in older adults.
Our last two reviews focus on various aspects regarding
the biology of aging and how syndromes associated with
aging may impact tolerance to certain anti-neoplastic therapies. Al-Jumalyi et al, speciﬁcally discuss biologic mechanisms of both aging and radiotherapy damage and how
radiotherapy may accelerate the aging process. In the ﬁnal
review, Extermann and team discuss the potential future of
personalized medicine for older adults. By combining biology and potential markers of aging, functional assessments
that predict toxicity, patient-reported outcomes, and
improvements in Artiﬁcial Intelligence (AI), clinicians in the
near future will hopefully be able to better predict the true
risk and beneﬁts of treatment options for each individual
older adult with cancer.
Of course, this issue does not encompass all of the important topics in geriatric oncology. However, we hope that this
special edition will encourage oncologists, and radiation
oncology teams in particular, to take a more active role in
assessing and improving cancer care for older adults. We
also hope that in 10 years from now, a new special edition
will highlight all of the excellent work done in older adult
studies performed in oncology clinics throughout the world.
We would like to thank all of the authors who contributed
to this edition for their hard work and expertise. We would
also like to thank our mentors and mentees who continue to
teach us every day. Special thanks to our families for their
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continued support and patience. Finally and most importantly, we would like to particularly thank our older cancer
patients and let them know that just like the beautiful and
deep tones of an older ﬁddle, the depth of experience and
wisdom of age that they share is profoundly inspiring to us.
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